Life Sciences

  • August 31, 2026

    Mead Johnson Prevails In 1st Infant Formula MDL Trial

    An Illinois federal jury sided with Mead Johnson on Monday in a lawsuit claiming its infant formula caused a premature baby boy to develop a fatal intestinal disease, rejecting his mother's claims that the company should be held liable for making a defective product and failing to adequately warn doctors of the risks associated with it.

  • August 31, 2026

    Ropes-Steered Lilly To Buy Goodwin-Led Merida For $2.9B

    Eli Lilly and Co., advised by Ropes & Gray LLP, said Monday that it has agreed to pay up to $2.875 billion in cash to purchase autoimmune- and allergic disease-focused biotech Merida Biosciences Inc., which is being advised by Goodwin Procter LLP.

  • August 28, 2026

    Mead Johnson, Mom Clash On Formula Risks In Trial Closing

    An Illinois federal jury is set to begin deliberating Monday on a mother's claims that Mead Johnson is liable for her infant son's death, with attorneys making closing remarks Friday in the first test case to be tried among more than 800 consolidated lawsuits linking a deadly bowel condition to premature baby formula.

  • August 28, 2026

    AbbVie 'Concocted' Cancer Drug IP Claims, Biotech Firm Says

    Biotech firms ProfoundBio and Genmab urged a Seattle federal judge Thursday to throw out rival AbbVie's lawsuit accusing two of its former employees of taking trade secrets on cancer therapies to ProfoundBio, arguing AbbVie's claims are time-barred, and the information wasn't a protectable trade secret.

  • August 28, 2026

    Walmart Pays $50M To End DOJ's Suit Over Opioid Crisis

    Walmart has agreed to pay $50 million to settle the U.S. Department of Justice's nearly 6-year-old lawsuit in Delaware federal court alleging the big-box retailer helped spur the nationwide opioid crisis by unlawfully dispensing controlled drugs from its pharmacies, the department announced Friday.

  • August 28, 2026

    Mylan, Lannett, Others Can't Split Up Humana Generics Trial

    A Pennsylvania federal judge refused Friday to let Mylan, Lannett and other generic-drug makers split up Humana's looming price-fixing trial between liability and damages, preferring a single go in front of a single jury for the first trial in the sprawling multidistrict litigation.

  • August 28, 2026

    AI-Bolstered Drug Co. Hits Ch. 11 With $105M Debt

    A company that uses artificial intelligence to explore new uses for existing drugs entered bankruptcy in Delaware with over $104 million in debt and a stalking horse bidder.

  • August 28, 2026

    Parse Owes $4.9M In Cell Analysis Patent Case, Jury Finds

    A Delaware federal jury put Parse Biosciences Inc. on the hook for $4.9 million after finding Friday that the biotechnology company infringed a trio of Roche Sequencing Solutions Inc. patents covering a way of detecting target molecules in cell samples.

  • August 28, 2026

    Rising Star: Ropes & Gray's Ray Grant

    Ray Grant of Ropes & Gray LLP advised Bain Capital portfolio company Tanabe Pharma Corp. in a $2.5 billion sale of the global rights to a treatment for ALS, earning him a spot among the life sciences law practitioners under age 40 honored by Law360 as Rising Stars.

  • August 28, 2026

    Medical Marijuana Industry Grapples With DEA's New Role

    After years of allowing the state-sanctioned medical marijuana industry to operate without interference, the U.S. Drug Enforcement Administration is stepping in to regulate a drug it once treated exclusively as contraband, but attorneys and regulators say the cannabis industry's interactions with the agency are off to a rocky start.

  • August 28, 2026

    Fla. Says PBMs Fixed Prices For Prescription Drugs

    Florida's attorney general on Thursday sued two competing pharmacy benefit managers for allegedly colluding to fix prescription drug reimbursement rates to pharmacies, which the state said threatens Floridians' access to affordable medications.

  • August 28, 2026

    4 Arguments For Benefits Attys To Watch In September

    The Fifth Circuit will weigh Louisiana's bid to block telehealth access to the abortion drug mifepristone, while the Fourth Circuit will hear Lockheed Martin's challenge to a trial court decision that kept a pension de-risking suit alive. Here's a look at these and other argument sessions that should be on benefits attorneys' radar next month.

  • August 27, 2026

    PBMs Hammer Opioid Judge In Last-Ditch Gambit At 6th Circ.

    An Ohio federal judge knowingly flouted a Sixth Circuit rebuke by forcing two of the largest remaining defendants in multidistrict opioid litigation to either "settle for enormous sums or litigate for years hundreds of cases," says a Thursday petition urging the appeals court to intervene.

  • August 27, 2026

    Albertsons Loses Bid For Midtrial Win In Wash. Opioid Case

    Albertsons can't escape the state of Washington's lawsuit accusing the pharmacy chain and its Safeway subsidiary of contributing to the state's opioid crisis, a state judge ruled Thursday in denying the company's bid to dismiss the case midtrial.

  • August 27, 2026

    Mead Johnson Nutrition Head Defends Formula In MDL Trial

    Mead Johnson's head of nutrition testified Thursday in a trial over whether its preterm infant formula led to a newborn's serious and ultimately fatal gut illness, saying she had no reasons to worry about the product's safety but acknowledging it carries a higher risk for the disease than human breast milk.

  • August 27, 2026

    5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight

    The U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national drug shortage list, the Fifth Circuit ruled Thursday, handing a loss to compounding pharmacies that produce copycat doses of the drugs.

  • August 27, 2026

    Guardant Suits Against Tempus AI Clear Dismissal Bids

    A Delaware federal judge has refused to throw out litigation accusing Tempus AI Inc. of infringing Guardant Health Inc. patents covering technology used to analyze cancer-related genetic data and help guide testing and treatment.

  • August 27, 2026

    23andMe Judge Slows Estimation Of Calif. Data Breach Claim

    A Missouri bankruptcy judge ruled Thursday he would split a process for dealing with data breach claims brought by the state of California against 23andMe into two stages, saying he would first decide whether the bankruptcy trust for the DNA testing company should be allowed to estimate the state's claims for damages.

  • August 27, 2026

    Mich. Hospitals Defend CVS 340B Drug Savings Suit

    University of Michigan Hospitals and Health Centers urged a Michigan federal judge Wednesday to preserve its suit claiming that CVS Health Corp. diverted millions of dollars earmarked for indigent healthcare to itself, saying the conduct clearly amounts to a racketeering scheme.

  • August 27, 2026

    USPTO Sets Radiation Monitoring Patent Order As Informative

    The U.S. Patent and Trademark Office has added weight to a Patent Trial and Appeal Board order from earlier this year that undid a decision rejecting an RNA patent application.

  • August 27, 2026

    Rising Star: Goodwin's Heath Ingram

    Heath Ingram of Goodwin Procter LLP advised Avadel Pharmaceuticals on its launch of a U.S. Food and Drug Administration-approved narcolepsy drug and then its $2.37 billion sale to fellow Irish drugmaker Alkermes, earning him a spot among life sciences attorneys under age 40 honored by Law360 as Rising Stars.

  • August 26, 2026

    5th Circ. Upholds Drug Negotiations In Blow To Big Pharma

    Medicare's landmark program of drug price negotiations doesn't flout constitutional provisions involving the separation of powers, due process or excessive fines, the Fifth Circuit ruled late Wednesday, delivering a fresh blow to the pharmaceutical industry's campaign to tee up U.S. Supreme Court review.

  • August 26, 2026

    Eton's Galzin TM And False Ad Suit Survives Dismissal Bid

    Eton Pharmaceuticals can proceed with trademark infringement and false advertising claims accusing Extreme V of marketing a dietary supplement as a Wilson disease treatment, with a Michigan federal judge finding that Extreme V's defenses and factual challenges could not dispose of the case at the pleading stage.

  • August 26, 2026

    Humana Keeps Conspiracy Claims Against Mylan, Lannett

    A federal judge refused to grant Mylan and Lannett summary judgment on claims in Humana's suit alleging a conspiracy to fix the prices of generic drugs ahead of its bellwether trial, calling it premature and noting that the other parties did not join the motion.

  • August 26, 2026

    2nd Circ. Says Shield Law Covers Doctor In COVID Death Suit

    The Second Circuit on Wednesday affirmed the dismissal of a Connecticut estate's malpractice suit alleging a doctor negligently prescribed high doses of prednisone to an elderly COVID-19 patient who subsequently died of organ failure, finding the suit is barred under the Public Readiness and Emergency Preparedness Act.

Expert Analysis

  • Series

    Choral Singing Makes Me A Better Lawyer

    Author Photo

    Singing in the New York City Bar Chorus — a hobby partly inspired by the late U.S. District Judge Richard Owen, who infused my clerkship year with opera music — has improved my legal career by refining my abilities to listen, exude confidence and develop emotional intelligence, says Bonnie Baker at Friedman Kaplan.

  • Attorney Mental Health Is An Ethical Obligation In The AI Era

    Author Photo

    As attorneys cope with the increasing unpredictability that artificial intelligence and constant policy changes have created, particularly in practice areas where they carry the emotional weight of clients’ most consequential life events, otherwise soft discussions about self-care are a matter of professional competence, says attorney Jack Jrada.

  • The Case For Using Final-Offer Damages Forms In IP Suits

    Author Photo

    Recent Federal Circuit decisions, such as Ollnova v. Ecobee, that scrutinize verdict forms in patent infringement disputes potentially render the final-offer damages selection procedure more attractive, though it should not be seen as a replacement for patent damages doctrine, says Brandon Theiss at Addy Hart.

  • Key Tips For Patenting Antibody-Drug Conjugate Inventions

    Author Photo

    Recent decisions highlight the significant challenges that can arise when patenting antibody-drug conjugates, which require strategic considerations for satisfying heightened written description and enablement requirements, says Xiaoban Xin at FisherBroyles.

  • $885M IBS Drug Verdict Tests Pay-For-Delay Limits

    Author Photo

    The outcome in the Amitiza Antitrust Litigation is significant because it is the first jury trial win for private antitrust plaintiffs in a suit challenging a patent settlement reverse payment since the U.S. Supreme Court adopted the rule-of-reason legal framework in 2013, offering a blueprint for pay-for-delay claims, say attorneys at Katten.

  • Series

    Power To The Paralegals: Burnout As A Structural Problem

    Author Photo

    Law firm leadership can best retain their paralegals not by encouraging self-care, but by seeking top-down structural solutions for the quiet proliferation of responsibilities and the vicarious exposure to client trauma that particularly drive burnout in this vital role, says Erika Sneeringer at Brockstedt Mandalas.

  • Class Actions At The Circuit Courts: June Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five recent rulings from cases involving allegations of internet data misuse, consumer fraud claims, immigration, insurance and First Amendment violation claims.

  • Takeaways From 1st Del. Ruling Applying Moelis Amendments

    Author Photo

    Delaware corporations should carefully review contractual arrangements and governance documents following the Court of Chancery's recent enforcement of a non-Delaware forum selection clause in a CEO's employment agreement under 2024 amendments to the state's General Corporation Law, say attorneys at Morgan Lewis.

  • Ill. Law Firm MSO Bill Clashes With Court Power, Ethics Rules

    Author Photo

    An Illinois bill prohibiting law firms from certain business arrangements with management service organizations, sent to the governor for signature last week, encroaches upon the courts' constitutional powers and goes beyond the Illinois Rules of Professional Conduct in regulating investment in law-related services, says Matthew O’Hara at Smith Gambrell.

  • The Future Of WDTX Patent Litigation After Judge Albright

    Author Photo

    With U.S. District Judge Christopher Wolfe set to take over much of Judge Alan Albright's patent infringement docket in the Western District of Texas later this year, attorneys should prepare for potential differences in Judge Wolfe's approach to the court's high volume of patent litigation, say attorneys at Sidley Austin.

  • Opinion

    State Courts Must Be Gatekeepers Of Expert Testimony

    Author Photo

    Based on my experience in the state judiciary, emulating federal courts' role as gatekeepers of expert witness testimony would help state court judges maintain the appearance of impartiality and assist juries, thus enhancing the overall confidence people have in their justice system, says Lorie Gildea at Greenberg Traurig.

  • 5 Key Factors Behind USPTO's Inter Partes Review Decisions

    Author Photo

    Though U.S. Patent and Trademark Office Director John Squires has drawn criticism for failing to explain his reasoning in inter partes review decisions, his recent precedential order in Magnolia v. Kurin provides five important insights into his decision-making process, says Christopher Loh at Venable.

  • Series

    Moshing Makes Me A Better Lawyer

    Author Photo

    Entering a mosh pit is much like entering the practice of law — it is difficult, you have to know both the written and unwritten rules, and conduct yourself according to the expectations of each community, says Christopher Deubert at Constangy Brooks.

  • High Court Ruling Casts Doubt On Status-Based Gun Bans

    Author Photo

    The U.S. Supreme Court’s recent ruling in U.S. v. Hemani demonstrates that the justices are increasingly skeptical of broad theories of categorical disarmament and clarifies that dangerousness cannot simply be presumed from one's status or membership in a statutory category, such as illegal drug use, says Lee Francis at Widener Law.

  • Why Highly Specialized Experts May Risk Exclusion At Trial

    Author Photo

    Expert witnesses with highly specific areas of focus may be vulnerable to exclusion in court, making it important for attorneys to check how potential witnesses' qualifications can be bolstered by their publications and other professional activities, say Evan Weisberg and Christopher Cunio at Hunton, and Kevin Cahill at FTI Consulting.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.